Iovance Biotherapeutics, Inc. (IOVA) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Iovance Biotherapeutics, Inc. (IOVA) closed at USD 14.21 on 2026-10-14, a change of +548.9 % over the past year, with a market capitalization of USD 6.67B.

Iovance Biotherapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Iovance Biotherapeutics, Inc. key figures

Previous close

USD 14.21 (2026-10-14)

1-year change

+548.9 %

Market cap

USD 6.67B

Enterprise value

USD 6.42B

P/E ratio (trailing)

-21.03

P/E ratio (forward)

-75.20

EPS (trailing)

-0.70

EPS (forward)

-0.20

PEG ratio

n/a

Price to book

9.06

Revenue growth

65.7 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.69

Employees

975

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Iovance Biotherapeutics, Inc. and compare it with other stocks.